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Chemokine Receptors in T-Cell-Mediated Diseases of
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Anke S. Lonsdorf1, Sam T. Hwang2 and Alexander H. Enk1
The chemokine/chemokine receptor network is an integral element of the complex system of homeostasis
and immunosurveillance. Initially studied because of their role in coordinating tissue-specific migration and
activation of leucocytes, chemokines have been implicated in the pathogenesis of various malignancies and
diseases with strong inflammatory components. We discuss recent findings suggesting a critical involvement of
chemokine receptor interactions in the immunopathogenesis of classical inflammatory skin disorders such as
psoriasis and atopic dermatitis, as well as neoplastic diseases with a T-cell origin, such as mycosis fungoides. A
deeper understanding of the underlying contribution of the chemokine network in the disease processes is key
for the development of selective targeted immunotherapeutics that may meet the delicate balance between
efficacy and safety.
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INTRODUCTION
In the past two decades, chemokine
receptors have emerged as important
determinants for the directed trafficking
of T cells and their function in primary,
effector, and memory immune respon-
ses (Sallusto et al., 2000). Although their
role in leukocyte activation and differ-
entiation is well established, it is becom-
ing increasingly clear that chemokine
receptor/ligand interactions participate
in several other key biological processes
such as apoptosis, tumorigenesis, and
antimicrobial activity (Zlotnik et al.,
1999; Rossi and Zlotnik, 2000).
A comprehensive discussion of the
biology of chemokines has been the
focus of several recent publications
(Luster, 1998; Rossi and Zlotnik,
2000; Charo and Ransohoff, 2006;
Bromley et al., 2008) and is beyond
the scope of this review.
Instead, we aim to highlight the
areas of chemokine biology with parti-
cular impact on the immunopatho-
genesis of classical T-cell-mediated
skin diseases, such as psoriasis, atopic
dermatitis (AD), and mycosis fungoides
(MF), and discuss possible implica-
tions in the development of novel
targeted therapies. The structural orga-
nization of the skin allowing direc-
tional migration of leucocytes within
the two defined compartments of the
epidermis and dermis, as well as its
convenient accessibility, identifies the
skin as an ideal model for in vivo
studies on chemokine involvement
in the pathogenesis of defined skin
disorders.
THE CHEMOKINE SYSTEM
Chemokines are small (8–11 kDa),
secreted proteins that are predomi-
nantly involved in regulating leuko-
cyte chemoattraction (Luster, 1998).
The approximately 50 identified mem-
bers of the chemokine superfamily are
systematically subcategorized on the
basis of the position and number of
conserved cysteine motifs in one out of
four related families: C, CC, CXC, and
CX3C chemokines (Rossi and Zlotnik,
2000). On the basis of their constitutive
or inducible production under homeo-
static or inflammatory conditions,
chemokines can be further classified
into inflammatory or homeostatic
chemokines.
Chemokines interact with members
of the large family of seven-transmem-
brane G-protein-coupled receptors
(Charo and Ransohoff, 2006). The
C-terminal intracellular domain of the
receptor is involved in receptor signal-
ing and internalization, whereas the
extracelluar acidic amino-terminal por-
tion mediates ligand binding. To date,
approximately 18 different chemo-
kine receptors have been molecularly
defined (Mantovani et al., 2006).
Notably, there is considerable
redundancy in the chemokine network,
with chemokines binding to more than
one receptor and vice versa.
DIFFERENTIAL CHEMOKINE
RECEPTOR EXPRESSION ON
T-CELL SUBSETS
Chemokine receptors have emerged as
important determinants for the pheno-
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typical and functional characterization
of distinct T-cell subsets. The signifi-
cance of a deeper insight into the role
of the chemokine/chemokine receptor
network in the immunopathogenesis
of T-cell-mediated skin diseases arises
essentially from the observation that
distinct subsets of pathogenic effector
leucocytes are preferentially recruited
in different T-cell-mediated skin dis-
eases, three of which will be discussed
as examples in this review.
Different subsets of T-helper cells
can develop from naive CD4þ T cells
and may be characterized by a dis-
crete pattern of cytokine production.
Although IFN-g-producing Th1 cells
are thought to primarily promote cell-
mediated immune responses, Th2 cells,
which secrete IL-4, IL-5, and IL-13, are
mostly involved in humoral immunity,
including allergic reactions. lL-17 and
IL-22 have been described as the hall-
mark cytokines of Th17 cells, a newly
described T-helper subset with consid-
erable involvement in several inflam-
matory and autoimmune diseases
(Hirota et al., 2007; Pene et al., 2008).
In cutaneous T-cell lymphoma
(CTCL), the malignant cell is thought
to typically derive from a Th2-polarized
origin. In AD, Th2 cells are pre-
dominantly implicated in the early
phase of the disease. In contrast,
chronic lesions of AD are characterized
by an accumulation of skin-homing
T cells with a Th1 phenotype (Grewe
et al., 1998). By contrast, the inflam-
matory infiltrate in psoriasis is predo-
minantly composed of Th1-polarized
lymphocytes of a memory phenotype
as well as neutrophils, macrophages,
and increased numbers of dendritic
cells (DCs) (Prens et al., 1995). In
addition, Th17 cells have recently
been implicated in the pathogenesis
of psoriasis and other autoimmune
inflammatory diseases (Lowes et al.,
2007; Steinman, 2007; Zaba et al.,
2007).
Over the past decade, the close
association of chemokine receptor
expression with the functional pro-
perties, differentiation, and maturation
status of T-cell subsets has been con-
vincingly documented. Th1 cells have
been reported to selectively express
CXCR3 and CCR5 (Loetscher et al.,
1998; Sallusto et al., 1998a) and show
migration in response to CCL3-5 and
CXCR9-11. By contrast, Th2 cells have
been found to preferentially express
CCR4 (Bonecchi et al., 1998; Sallusto
et al., 1998a), CCR8, and, to a lesser
extent, CCR3 (Sallusto et al., 1997), and
can be selectively recruited by the
respective chemokines (CCL17, CCL22,
CCL1, and CCL11). CCR6 has recently
been described as a marker for human
and murine Th17 cells, identifying the
vast majority of IL-17-producing T cells
in human peripheral blood (Acosta-
Rodriguez et al., 2007; Annunziato
et al., 2007; Singh et al., 2008).
CCR4 has been found to be abun-
dantly expressed on many systemic
peripheral blood memory T cells,
which consequently respond to its
ligands, the chemokines, CCL17 and
CCL22 (Campbell et al., 1999). Inter-
estingly, these cells include essentially
all T cells with a skin-homing CLAþ
phenotype, regardless of their Th1 or
Th2 polarization (Andrew et al., 2001).
Further studies examining the T-cell
chemokine receptor expression in vivo
indicate that the patterns and regula-
tion of chemokine receptor expression
in vivo are more complex than those
suggested by present in vitro models
of Th1 versus Th2 cell generation. Kim
et al. (2001) reported that in vivo-
activated Th1 and Th2 cells display a
remarkable heterogeneity with regard
to their chemokine receptor expression.
Similarly, the IL-17-secreting subset of
T-helper cells, as well as the population
of antigen-specific Foxp3þ regulatory
T cells, seems to be heterogeneous with
regard to chemokine receptor expres-
sion. T regulatory cells (Treg) and Th17
cells share chemokine receptors with
other T-cell lineages and might differ-
entiate to have distinct chemokine
receptor expression profiles depending
on the microenvironment in which
they are activated (Acosta-Rodriguez
et al., 2007; Bromley et al., 2008).
Although the observed heterogeneity
and flexible programing of chemo-
kine receptor expression might be an
advantageous feature for the migratory
potential to diverse tissues in vivo,
these studies call the physiological
relevance of several in vitro observa-
tions into question.
TRADITIONAL FUNCTIONS AND
NEW ASSIGNMENTS
Chemokine interactions have been
intensely studied for their significant
importance in the controlled regulation
of immune cell trafficking and activa-
tion. Recent studies indicate that
chemokines may have additional roles
and exert further key biological
functions, with possible implications
for the immunopathogenesis of T-cell-
mediated skin diseases.
Chemokine-mediated T-cell trafficking
to the skin
Molecular mechanisms controlling the
multistep process of directed migration
and tissue positioning are an area of
intense research. In response to antigen
encounter in secondary lymphoid
organs, activated T cells not only
acquire effector functions but also
achieve the capacity to efficiently
migrate to extralymphatic tissues, such
as the skin. The tissue-selective recruit-
ment of naive and memory T lympho-
cytes can largely be explained by the
joint expression of chemokine recep-
tors and adhesion molecules such as
selectins and integrins (Butcher and
Picker, 1996).
Chemokine receptor engagement is
thought to facilitate transmigration by
permitting the firm adhesion of rolling
lymphocytes to the luminal vascular
endothelium in an integrin-indepen-
dent manner (Campbell et al., 1998;
Campbell and Butcher, 2000; Fitzhugh
et al., 2000). Subsequently, chemokine
gradients in the skin may guide recep-
tor-bearing subsets of T cells to distinct
sites within the tissue compartment
(Hwang, 2001).
In humans, the expression of cuta-
neous lymphocyte antigen (CLA)
defines a subset of skin-homing T cells
with specific carbohydrate-mediated
binding to E-selectin, an adhesion
molecule highly expressed by endo-
thelial cells under inflammatory condi-
tions (Berg et al., 1991; Springer, 1994;
Fuhlbrigge et al., 1997).
Although CLAþ T lymphocytes
represent only 10–15% of circulating
T cells in the peripheral blood, Clark
et al. (2006) recently estimated that
90% of skin-resident T cells express
CLA, and 80% of these cells are
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effector memory T cells (Picker et al.,
1993). However, as E-selectin is not
exclusively expressed by the cutaneous
vascular complex but also on endo-
thelium in various tissues under inflam-
matory conditions, other skin-specific
factors seem to contribute to the hom-
ing of CLAþ T cells. CCR4 and CCR10
expression in particular seems to be
associated with a CLAþ skin-homing
phenotype of circulating T cells
(Homey et al., 2000a, 2002; Schaerli
et al., 2004) and has been found to
be critical for T-cell recruitment to
the skin in two different inflammation
models (Reiss et al., 2001; Campbell
et al., 2007).
The majority of CLAþ lymphocytes
in the peripheral blood co-expresses
CCR4 (Campbell et al., 1999), with
subsets (30–40%) showing additional
expression of CCR10 (Hudak et al.,
2002). The CCR10 ligand, CCL27, is
exclusively produced by epidermal
keratinocytes (Morales et al., 1999;
Homey et al., 2002) and CCL17—a
CCR4 ligand—is synthesized by acti-
vated keratinocytes, DCs, and endo
thelial cells in the skin (Campbell
et al., 1999; Campbell and Butcher,
2000). Although CCL17 expression is
not skin-specific, Reiss et al. (2001)
have suggested a model in which CCR4
and CCR10 share partly redundant or
overlapping roles in the recruitment of
leukocytes to the skin.
Apart from supporting immune
cell recruitment to tissues, chemo-
kines are thought to play an active
role in the positioning of distinct
T-cell subsets within different tissue
compartments.
Notably, a high binding affinity of
CCL27 to proteins of the extracellular
matrix has been documented, suggest-
ing a possible mechanism for the
maintenance of chemokine gradients
within the skin compartment (Homey
et al., 2002). In addition, the accumu-
lation of epidermal CCL27 in skin-
draining lymph nodes may influence
the homing of CCR10þ T cells (Huang
et al., 2008). Worbs et al. (2007)
recently reported that CCR7 ligands
present within secondary lymphatic
tissue stimulate the intranodal motility
and positioning of T cells in vivo.
Conclusive in vivo studies investigating
an analogous scenario for chemokines
expressed in the skin compartment are
eagerly awaited.
T-cell differentiation
The role of chemokine receptor expres-
sion as a determinant for the functional
properties and lineage commitment of
T-cell subsets has been the focus of
intense research efforts. Chemokines
may influence T-cell differentiation
indirectly by stimulating antigen-
presenting cells to induce or repress
polarizing cytokines, such as IL12
(Braun et al., 2000). Alternatively,
chemokines have been shown to regu-
late T-cell polarization by acting
directly on activated T cells (Karpus
et al., 1998). Experimental evidence
from several studies indicates that
CCR5–CCL3 and CCL2 interactions in
particular might be alternate or com-
plementary pathways to IL-12 and
IL-4 in dominating T-cell polarization
(reviewed by Luther and Cyster, 2001).
With immunotherapeutics targeting
the chemokine network forthcoming,
the disease-related contribution of
chemokine/chemokine receptor inter-
actions in Th1 and Th2-cell polariza-
tion and effector functions is evolving
(Kim et al., 2001).
Chemokine-mediated effects on
skin-resident DCs
Chemokine/chemokine receptor inter-
actions are not limited to targeting
naive, memory, and effector lympho-
cytes but extend to all subsets of leuco-
cytes, including mature leucocytes of
the innate immune system, as well as
their hematopoietic precursors (Moser
and Willimann, 2004).
Dendritic cells represent an integral
link between components of the innate
and the adaptive immune system. As
professional antigen-presenting cells,
they possess the unique ability to take
up and process antigen in peripheral
tissues to activate resting lymphocytes
in secondary lymphoid organs and
elicit an adaptive immune response.
Thus, the directed migration of DC
from the skin to the skin-draining
lymph nodes is an essential factor in
their immunostimulatory function and
pathogenetic involvement in T-cell-
mediated skin diseases.
The skin contains two major subsets
of DCs: dermal DCs and Langerhans
cells (LCs) in the epidermis (Loser
and Beissert, 2007; Udey and Nagao,
2008). A complex interplay between
cytokines, adhesion molecules, matrix
metalloproteinases, and lipid media-
tors, as well as chemokines and their
receptors, orchestrates the in situ posi-
tioning of DC and directs their reloca-
tion from peripheral tissues to the
draining lymph nodes (Moser and
Willimann, 2004; Adema et al., 2005).
During maturation, DCs undergo a
rapid and coordinated switch in their
chemokine receptor profile (Sallusto
et al., 1998b). Immature DCs have
been reported to express a distinct
subset of chemokine receptors, includ-
ing CCR1, CCR2, CCR5, CCR6, CCR8,
and CXCR1 (Villablanca et al., 2008),
enabling them to migrate to inflamed
tissues, including the skin (Gombert
et al., 2005). Conversely, CXCR4 and
CCR7 are expressed at very low levels
on immature DCs, but are markedly
upregulated once DCs undergo matu-
ration after antigen capture (Sallusto
et al., 1998b).
Although identifying CCR7 as an
indispensable regulator for the entry
of dermal DCs and LCs into afferent
dermal lympathics, studies from Ohl
et al. (2004) propose that CCR7 may be
dispensable for the initial step of LC
mobilization within the epidermis, that
is, migration from the epidermis toward
the dermis. Correspondingly, studies
using human skin explants revealed
that CXCR4 and its ligand, CXCL12,
expressed by dermal endothelial cells,
are crucial factors for LC migration
from the epidermis to the dermis,
whereas CCR7 is not essential (Avniel
et al., 2006; Ouwehand et al., 2008). In
addition, Kabashima et al. (2007a)
have confirmed an important role for
CXCR4 expression of mature DCs in
their migration to skin-draining lymph
nodes.
In light of these findings, a two-step
model for LC migration to skin-draining
lymph nodes has recently been pro-
posed by Villablanca and Mora (2008).
Under homeostatic conditions, imma-
ture LCs that do not express CXCR4
and CCR7 remain mostly confined to
the epidermis. In a first step, the
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upregulation of CXCR4 in response to
inflammatory stimuli is thought to
enable the maturing LCs to enter
the dermal compartment of the skin,
following a chemokine gradient of
enhanced CXCL12 expression by
dermal endothelial cells in inflamed
skin. TNF-a, expressed at elevated
levels in the skin under inflammatory
conditions such psoriasis or AD,
contributes to the disconnection
between LCs from the keratinocytes
of the epidermis by downregulating
CCR6 expression on maturing LCs
and thus rendering them insensitive
to keratinocyte-derived CCL20
(Randolph et al., 2005; Villablanca
et al., 2008). Once in the dermis, high
levels of CCR7 expression on their cell
surface subsequently permit the mature
LCs and dermal DCs to exit the tissue
and migrate to skin-draining lymph
nodes, where the CCR7 ligands,
CCL19 and CCL21, are readily ex-
pressed (Forster et al., 1999; Saeki
et al., 1999).
Along these lines, it is noteworthy
that besides the most extensively stud-
ied chemotactic effects, recent reports
have pointed toward new functions of
chemokine receptor interactions in DC
biology. Analogous to effects described
on T cells, CXCR4–CXCL12 interactions
might also affect LC survival and
maturation (Kabashima et al., 2007b),
whereas CCR7 engagement seems to
be involved in the regulation of cyto-
architecture and endocytosis, survival,
maturation, and the migratory speed of
DCs (Sanchez-Sanchez et al., 2006).
Survival pathways
Several chemokines have been
reported to trigger downstream pro-
survival signals. In particular, activa-
tion of the intracellular downstream
effector molecules, phosphatdylinositol-
3-kinase (P13K) and prokinase B (Akt),
has been shown to lead to increased
resistance to apoptosis on chemokine
receptor engagement (Youn et al.,
2002; Murakami et al., 2003). CCL1
has been described as a potent anti-
apoptotic factor for thymocytes, and
CCL1–CCR8 interactions have been
shown to provide survival signals to
malignant T cells in adult T-cell lym-
phoma (Ruckes et al., 2001). Murakami
et al. (2003) reported that CCR10
engagement by locally produced
CCL27 in the skin allows melanoma
cells to escape the host’s immune
antitumor killing mechanisms, possibly
through the activation of PI3K/Akt.
Similar mechanisms might contribute
to the survival and maintenance of
pathogenic T cells in the skin in other
neoplastic or inflammatory skin dis-
eases, in which selected chemokines
are abundantly expressed.
Microbicidal activity
In addition to providing a physical
barrier, keratinocytes of the human
epidermis constitutively or inducible
express a number of molecules with
bactericidal or bacteriostatic proper-
ties, such as human beta-defensins,
LL-37, psoriasin (S100A7), and cystatin
A (Harder et al., 1997; Schittek et al.,
2001; Zaiou and Gallo, 2002; Harder
et al., 2004; Glaser et al., 2005). The
protein family of these so called anti-
microbial peptides is a fundamental
element of the innate defense system
of epithelial and endothelial tissues,
including the skin.
Accumulating evidence indicates
that the members of the chemokine
family and antimicrobial peptides not
only share structural similarities but
also exert substantially overlapping
functions (Yang et al., 2002, 2003).
Although a number of antimicrobial
peptides are chemotactic for selected
classes and subsets of leukocytes (Yang
et al., 2004), many chemokines have
a substantial antimicrobial activity
against a broad range of microorgan-
isms (Yang et al., 2003). Human
b-defensins exhibit chemotactic activ-
ity by sharing the chemokine receptor,
CCR6, with its sole chemokine ligand,
CCL20, expressed in the skin by epi-
dermal keratinocytes and activated
endothelial cells (Yang et al., 1999).
Correspondingly, data from recent
studies suggest that CCL20 also
has antimicrobial activity, predomi-
nantly against Gram-negative bacteria
(Hoover et al., 2002).
For CCL28, an additional role in
mucosal immunity beyond being a
chemoattractant for CCR10- and/or
CCR3-expressing immune cells is being
implicated by studies from Hieshima
et al. (2003), reporting broad anti-
microbial activity of high concentra-
tions of CCL28 on mucosal surfaces.
For CCL27, the CCR10 ligand expres-
sed in the skin, the current data are
more controversial. In this regard, it is
noteworthy that most antimicrobial
assays are performed in vitro under
non-physiological conditions. A high
concentration of chemokines, low pH,
and salt-free conditions as used in
many assay systems are unlikely to
occur in vivo. However, the observa-
tion that chemokines, such as CCL27,
may reach high local concentrations
due to their high binding affinity to
proteins of the extracelluar matrix
(Homey et al., 2002) indicates that
chemokine measurements from bio-
logical fluids may significantly under-
estimate the levels reached in tissue
compartments, such as the skin.
Comprehensive screening showed
that about two-thirds of the 30 human
chemokines tested have antimicrobial
activity under the specific experimental
conditions (Yang et al., 2003).
It is persuasive to speculate that
different chemokine levels in diseased
skin may partially account for an
altered susceptibility to cutaneous bac-
terial infections, such as in AD.
However, the relative importance of
the antimicrobial activity of chemo-
kines in vivo remains a field of much
controversy and emphasizes the need
for testing in appropriate animal model
systems.
Decoy receptors
In addition to the traditional functions
of the signaling chemokine receptors
delineated above, a new group of non-
signaling chemokine-binding receptors
has recently been characterized by
virtue of their failure to initiate conven-
tional signaling cascades or mediate
chemoattraction.
Three of these so-called decoy
or scavenger receptors have been
described so far: D6, DARC (duffy
antigen receptor for chemokines), and
CCX–CKR (ChemoCentryx chemokine
receptor). Their unique structural and
functional properties, distinct specifi-
city and tissue distribution, as well
as their pivotal role in modulating
immune responses have been
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comprehensively discussed in a recent
review (Mantovani et al., 2006).
The best-characterized decoy recep-
tor, D6, is a promiscuous seven-trans-
membrane-domain G-protein-coupled
receptor, typically expressed on lym-
phatic vessels in the skin, gut, and lungs
(Nibbs et al., 2001). D6 binds most
inflammatory, but not homeostatic, CC
chemokines and is subsequently inter-
nalized in a ligand-independent way
from the plasma membrane to endocy-
tic compartments, wherein chemokines
are targeted for degradation (Weber
et al., 2004; Martinez de la Torre
et al., 2005).
Similar to D6, DARC shares struc-
tural similarities with a conventional
chemokine receptor but lacks the seq-
uence motif required for signal trans-
duction. DARC expression has been
reported on erythrocytes and endothe-
lial cells in tissues under steady state
and inflammatory conditions, including
the skin (Rot, 2005). Although binding
of homeostatic chemokines to DARC
has not been reported yet, DARC
interacts in a promiscuous manner with
several inflammatory chemokines of
both the CXC- and CC subfamilies
(Gardner et al., 2004). Data from
multiple studies indicate complex roles
of DARC in inflammation, tumorigen-
esis, and angiogenesis, and a lack of
DARC expression has been associated
with greater susceptibility to certain
tumors and inflammatory diseases
(Segerer et al., 2003; Bandyopadhyay
et al., 2006; Wang et al., 2006).
Recently, Pruenster et al. (2009) re-
ported that, unlike other known non-
signaling chemokine receptors, DARC
does not act as a decoy but instead
supports chemokine transcytosis and
chemokine-induced leukocyte migra-
tion in vitro and in vivo.
Nevertheless, studies from several
animal models have highlighted the
importance of chemokine scavenging
in the regulation of inflammatory and
antitumor immune responses in the
skin (Bonecchi et al., 1998; Shenoy
and Lefkowitz, 2003; Martinez de la
Torre et al., 2005; Nibbs et al., 2007).
D6-deficient mice show exacerbated
inflammatory responses in a model of
phorbol ester-induced skin inflamma-
tion, with prominent cutaneous T-cell
infiltration and psoriasiform changes
of the epidermis (Jamieson T, Nature
Immunol 2005). Conversely, a trans-
genic D6 expression in keratinocytes
was found to dampen cutaneous
inflammation and bestow substantial
protection from the development of
chemically induced skin tumors in
different animal models (Nibbs et al.,
2007). An expanded appreciation of
the complex biological activities and
functions of this newly identified group
of atypical chemokine receptors will
significantly contribute to a more
comprehensive understanding of the
pathophysiology of inflammatory and
neoplastic diseases.
THE CHEMOKINE NETWORK
IN THE PATHOGENESIS OF
T-CELL-MEDIATED SKIN DISEASE
Psoriasis
The fundamental contribution of che-
mokines in skin-specific leukocyte
homing and inflammation is shown
impressively in the pathogenesis of
psoriasis. Psoriasis, one of the most
common chronic inflammatory skin
disorders, is characterized by hyper-
proliferation of basal keratinocytes and
a prominent cutaneous inflammatory
infiltrate.
The inflammatory infiltrate of psori-
atic skin is predominantly composed
of Th1- and Th17-polarized lympho-
cytes of a memory phenotype, as well
as neutophils, macrophages, and
increased numbers of DCs (Prens
et al., 1995). An early cellular event
in the development of a psoriatic lesion
is the influx of activated T cells into
the affected skin, the proinflammatory
cytokines of which trigger a cycle of
cutaneous inflammation and epidermal
hyperplasia, resulting in the psoriatic
phenotype (Bata-Csorgo et al., 1995).
The complex cellular events leading
to psoriatic skin inflammation require a
controlled interplay between circulat-
ing leukocytes and resident skin cells
and seem to be vitally coordinated by
chemokine interactions (Table 1).
Studies from Homey et al. (2000b)
identified CCL27 as a new skin-specific
chemokine, exclusively produced by
epidermal keratinocytes (Morales et al.,
1999). In psoriatic patients, elevated
serum levels of CCL27, which corre-
late with disease activity, have been
reported (Morales et al., 1999; Homey
et al., 2002; Kakinuma et al., 2003a).
The constitutive expression of CCL27
by keratinocytes in the skin can be
upregulated by inflammatory mediators
(IL-1 and TNF-a), and is found at
elevated levels not only in psoriatic
lesions but also in Th2-dominated
inflammatory skin diseases, such as
AD (Homey et al., 2002). Thus,
CCL27–CCR10 interactions seem to be
involved in the recruitment of memory
T cells to the skin regardless of their
Th1 or Th2 polarization, and a CCL27
gradient in the skin has been postulated
to contribute to the epidermal position-
ing of CCR10þ T cells (Morales et al.,
1999; Homey et al., 2000b) (Figure 1).
In addition to CCR10, CCR4 is
highly expressed on a subset of mem-
ory T cells with a CLAþ skin-homing
phenotype, and both receptors seem to
cooperate in the recruitment of mem-
ory T cells to the skin under inflamma-
tory conditions (Reiss et al., 2001)
(Figure 1). Although the expression of
the CCR4 ligand, CCL17, is not skin
specific, its expression by the dermal
vascular endothelium under inflamma-
tory conditions may collaborate with
keratinocyte-derived CCL27 in mediat-
ing leukocyte migration into inflamed
skin.
Recent research has drawn attention
to the involvement of CCL20 and its
only known receptor, CCR6, in the
pathogenesis of psoriasis (Figure 1). In
lesional psoriatic skin, both CCL20 and
CCR6 have been detected at signifi-
cantly elevated levels (Homey et al.,
2000a). CCL20, primarily expressed by
epidermal keratinocytes and activated
endothelial cells, is a highly potent
chemoattractant for CCR6þ epithelial
Langerhans-type DCs and memory
T cells (Liao et al., 1999; Dieu-Nosjean
et al., 2000). Skin-homing CLAþ
memory T cells express high levels
of CCR6, and both CCL20 and CCR6
have been reported to colocalize with
epidermal T cells in psoriatic skin
(Fitzhugh et al., 2000; Homey et al.,
2000a). CLAþ T cells isolated from
psoriatic skin respond to lower con-
centrations of CCL20 as compared with
T cells from healthy donors, whereas
CCL20 production by keratinocytes
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can be induced by proinflammatory
cytokines (that is, IL-1 and TNF-a)
commonly found in psoriatic skin
(Homey et al., 2000a). Interestingly,
CCR6 has lately been described as a
marker for human and murine Th17
cells, and their hallmark cytokines
IL-17 and IL-22 have been implicated
to be critically involved in the
pathogenesis of several autoimmune
inflammatory diseases, including
psoriasis (Murphy et al., 2003; Langrish
et al., 2005; Acosta-Rodriguez et al.,
2007; Annunziato et al., 2007;
Blauvelt, 2008; Singh et al., 2008).
A recent study assessed the role of
CCR6 in an IL-23-induced mouse
model of psoriasiform dermatitis in
which the psoriatic phenotype has
previously been reported to be predo-
minantly meditated by the Th17 cyto-
kine, IL-22 (Chan et al., 2006; Zheng
et al., 2007). Interestingly, CCR6-
deficient mice were resistant to IL-23-
induced psoriatic skin inflammation
in this model. Although the pathology
was absolutely dependent on CCR6
expression, further investiga-
tion surprisingly revealed that CCR6
is mainly required for the recruit-
ment and/or function of a non-
T-cell source of IL-22 in this model
(Hedrick et al., in press).
Atopic dermatitis
Atopic dermatitis, or atopic eczema, is
a common pruritic and chronically
relapsing inflammatory skin disease
with a steadily increasing prevalence
(Leung and Bieber, 2003; Asher et al.,
2006). The pathogenesis of AD is
generally multifactorial and may
involve both genetic and environ-
mental factors (Palmer et al., 2006;
Weidinger et al., 2007). Acute lesions
emerge as erythematous macules or
papules with a typical distribution
pattern and severe pruritus, whereas
chronic lesions show characteristic
lichenification or thickening and
hypertrophy of the epidermis.
In addition to acanthosis and
hyperkeratosis, AD skin lesions show
histopathologically a marked inflam-
matory infiltrate, predominantly con-
sisting of CLAþ CD4þ memory
T cells (Leung and Bieber, 2003).
Clinical and experimental evidence
points toward a crucial role of the
composition of the T-cell infiltrate
in the immunopathogenesis of the
disease (Woodward et al., 2001; Leung
and Bieber, 2003).
Chemokines have complex func-
tions regarding the development and
composition of the inflammatory infil-
trate in AD (Table 1). Homey et al.
(2006) recently suggested an amplifica-
tion cycle of atopic skin inflammation
in which chemokine interactions play a
critical role. Patient scratch is thought
to induce mechanical injury and facili-
tate superinfection of atopic lesions,
resulting in the production of proin-
flammatory cytokines and chemokines,
which are thought to orchestrate the
recruitment of pathogenic leukocytes
into the skin. Although multiple
homeostatic and inflammatory chemo-
kines have been shown to relate to the
AD phenotype (reviewed by Homey
Table 1. Synopsis of main chemokine/chemokine receptor interactions reported to be involved in the pathogenesis
of psoriasis, atopic dermatitis and/or mycosis fungoides/Se´zary syndrome
Chemokine
receptor
Ligand(s) expressed
in the skin (alternate
acronym)
Preferential expression
on T-cell subsets Disease connection References
CCR4 CCL17 (TARC)
CCL22 (MDC)
Skin-homing CD4+ CLA+
T cells
Th2 cells
Th17 cells
Treg
Mycosis fungoides
Se´zary syndrome
Atopic dermatitis
Psoriasis
Fierro et al. (2006); Sokolowska-Wojdylo et al. (2005);
Campbell et al. (1999); Kakinuma et al. (2001);
Ishida et al. (2003)
CCR6 CCL20 (MIP-3a, LARC) Th17 cells
Treg
Psoriasis Homey et al. (2000a); Kleinewietfeld et al. (2005);
Hedrick et al. (in press)
CCR8 CCL1 (1309) Th2 cells,
gd T cells
Treg
Atopic dermatitis Gombert et al. (2005)
CCR10 CCL27 (CTACK) Skin-homing CLA+ CD4+,
and CD8+ T cells
Psoriasis
Atopic dermatitis
Mycosis fungoides
Hudak et al. (2002); Morales et al. (1999);
Homey et al. (2000b); Homey et al. (2002);
Notohamiprodjo et al. (2005);
Sokolowska-Wojdylo et al. (2005);
Kakinuma et al. (2003a, b)
? CCL18 Receptor unknown,
CCL18 induces migration of
CLA+ memory T cells into
the skin
Atopic dermatitis Pivarcsi et al. (2004); Park et al. (2008)
CXCR3 CXCL9 (MIG)
CXCL10 (IP-10)
CXCL11 (IP-9, I-TAC)
CD4+ CD45RO+ T cells Psoriasis
Low-grade mycosis
fungoides
Flier et al. (1999); Kallinich et al. (2003)
CXCR4 CXCL12 (SDF-1) CD4+ CD45RO+ T cells Mycosis fungoides Kallinich et al. (2003)
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et al., 2006), the roles of CCR10 and
CCR4 in AD have been particularly
well documented (Figure 2).
Both CCR10 and its ligand, CCL27,
exhibit strong immunohistochemical
staining in skin biopsies from AD
patients (Vestergaard et al., 2003).
CCL27, constitutively expressed by hu-
man keratinocytes, can be upregulated
by proinflammatory cytokines (that is,
IL-1 and TNF-a) present in inflamed
tissue (Morales et al., 1999; Homey
et al., 2002), and serum levels of
CCL27 show a significant correlation
with disease severity (Kakinuma et al.,
2003a). In mouse models mimicking
AD and allergic contact dermatitis,
neutralization of CCL27 resulted in a
significantly impaired memory T-cell
recruitment to the skin and a decreased
tissue inflammation (Homey et al.,
2002).
Th2 clones derived from the lesional
skin of AD patients have been found to
highly express CCR4 on their surface,
but little or no CXCR3 (Campbell et al.,
1999; Biedermann et al., 2002). Corre-
spondingly, high levels of the CCR4
ligands, CCL17 and CCL22, have been
detected in the lesional skin of AD
patients and in the skin of a mouse
model of AD (NC/Nga model) (Galli
et al., 2000; Vestergaard et al., 2003).
Similar to CCL27, the plasma levels of
the CCR4 ligands, CCL17 and CCL22,
show an elevated level in AD patients
compared with those in healthy con-
trols, and seem to correlate closely with
disease activity (Kakinuma et al., 2001;
Wakugawa et al., 2001). Although the
contribution of both CCL17 and CCL27
for the recruitment of memory T cells to
sites of skin inflammation is well
established, a specific association with
an AD phenotype has not been demon-
strated (Figure 2).
By contrast, a comprehensive study
of the expression of chemokines
in various chronic inflammatory or
autoimmune skin diseases revealed a
specific association of the chemo-
kine, CCL18, with an AD phenotype
(Pivarcsi et al., 2004). The CCL18
mRNA expression in lesional skin from
AD patients was found to be more than
100-fold higher than levels of CCL17.
An additional DNA microarray analysis
revealed the strongest association of
CCL17 with AD, compared with DNA
isolated from skin of psoriasis patients
or from healthy controls. In addition, a
recent study showed an increased
protein expression of CCL18 in the
serum of patients with extrinsic AD,
compared with patients with non-aller-
gic type of AD (intrinsic AD), with a
significant decrease after specific
immunotherapy (Park et al., 2008).
Although the receptor for CCL18 has
yet to be identified, CCL18 has been
reported to bind to CLAþ memory
T cells in the blood of AD patients
in vitro and induce their migration into
human skin in vivo (Gunther et al.,
2005).
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Figure 1. Roles for chemokines and their receptors in psoriasis. Common events in lesional psoriatic skin include activation of skin dendritic cells and
keratinocytes, recruitment and activation of predominantly Th1- and Th17-polarized T cells, followed by keratinocyte damage. Inflammatory mediators
(TNFa, IL-1, and so on) enhance the production of CCL27 by keratinocytes, as well as endothelial cell-derived CCL17, and may collaborate in mediating
the homing of CCR10þ CCR4þ skin-homing memory T cells to the site of cutaneous inflammation. In addition, elevated levels of CCL20 may further
contribute to the homing and in situ positioning of CCR6þ memory Th17 cells in psoriatic skin.
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In light of these findings, it is
noteworthy that CCL18 was reported
to be produced mainly by dermal DCs
in close proximity to infiltrating T cells
in atopic skin and to be strongly
induced by allergen exposure and
staphylococcal superantigens (Pivarcsi
et al., 2004). Interestingly, 90% of AD
patients show a colonization of lesions
with Staphylococcus aureus, and anti-
staphyloccocal therapy frequently sup-
ports a clinical improvement (Breuer
et al., 2000, 2002) (Figure 2).
In addition to CCL18, CCL1 has
recently been found to be another
chemokine that is specifically and
selectively upregulated in AD com-
pared with other inflammatory skin
disorders and healthy skin (Gombert
et al., 2005) (Figure 2). Gombert et al.,
identified mast cells and endothelial
cells as the major source of CCL1
during atopic skin inflammation and
demonstrated that, analogous to
CCL18, CCL1 expression can be
significantly induced by S. aureus
superantigens and by allergen
exposure. CCR8, the sole receptor for
CCL1, was abundantly expressed on
subsets of DCs in vitro, as well as on a
small subset of circulating T cells
(Bonecchi et al., 1998). Interestingly,
CCL1 has been previously described
as a potent antiapoptotic factor for
thymocytes (Ruckes et al., 2001).
CCR8 interactions may thus not only
contribute to immune cell recruitment
but also to their maintenance and
survival at sites of atopic skin inflam-
mation.
The specific association of CCL18
and CCL1 with an AD phenotype, in
conjunction with its regulation by aller-
gen exposure and microbial products, is
suggestive of a significant involvement
of CCL18 and CCL1/CCR8 interactions
in the induction and/or augmentation of
atopic skin inflammation.
Mycosis fungoides and Se´zary syndrome
Mycosis fungoides is the prototypic
and most frequent form within the
broad group of CTCLs, accounting for
approximately 72% of reported CTCL
cases (Weinstock and Gardstein, 1999;
Criscione and Weinstock, 2007). In
MF, the neoplastic T cells display a
strong epidermotropism and preferen-
tially localize to the skin.
Although a de novo presentation of
the advanced stages of the disease are
possible, MF classically presents itself
with a slow, indolent course that may
progress over years from patches and
plaques to tumor stages, and with a
possible subsequent involvement of
lymph nodes and the peripheral blood.
The Se´zary syndrome (SS), which was
previously often categorized as a var-
iant of MF, has now been classified as
a separate entity by WHO and EORTC
(Willemze et al., 2005). According
to ISCL (International Society for
Injury
Allergen
Bacterial superantigen
Proinflammatory cytokines
Epidermis
CCR4 CCR10
CCL1
CCL1
CCR8
CCR8
CCR4
CCL17
CCL22
CCL27
CCR10
?
?
CCL18
Dermal blood vessel
E-selectin         
CLA  
CLA
DC
Th2
Th2
MC
TNF-α IL-1
Figure 2. Roles for chemokines and their receptors in atopic dermatitis. Mechanical injury, such as patient scratch, and superinfection trigger atopic skin
inflammation by the induction of inflammatory cytokines and chemokines. CCL17–CCR4 and CCL27–CCR10 interactions contribute to the extravasation
and homing of CLAþ memory T cells to the site of cutaneous inflammation. CCL18 production by skin-resident DC can be strongly induced by allergen
exposure as well as by staphylococcal superantigens, and is thought to further sustain the migration of CLAþ memory T cells from the peripheral blood
to atopic skin lesions. In addition, CCL1 production by endothelial cells and mast cells during atopic skin inflammation may contribute to the recruitment
of CCR8-expressing T cells and DC, as well as sustaining their maintenance and survival at the site of cutaneous inflammation (MC: mast cell; ?: unknown
receptor).
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Cutaneous Lymphoma), the diagnosis
of SS is based on the verification of an
extensive, clonal population of abnor-
mal T cells with hyperconvoluted,
cerebriform nuclei in the peripheral
blood in addition to erythroderma.
Histologically, patches and plaques
of MF are characterized by the often
band-like accumulation of lympho-
cytes in the upper dermis and fairly
specific Pautrier microabscesses, con-
sisting of aggregates of malignant
T cells clustering around LCs in the
epidermis (Pimpinelli et al., 2005).
However, an early disease of MF and
SS may not show the entirely devel-
oped typical histopathological changes
and can clinically mimic benign
inflammatory skin disorders such as
psoriasis and AD, often impeding an
early diagnosis.
Although development and disease
activity seem to be controlled by a
population of tumor-specific CD8þ
Tcells, the malignant cells are thought
to originate from CD4þ CD45ROþ
memory T cells, which frequently lack
the expression of certain T-cell surface
markers, such as CD26, CD49d, and
CD7 (Vowels et al., 1994; Berger et al.,
1996; Bernengo et al., 2001). CD26,
also known as dipeptidylpeptidase IV,
proteolytically cleaves and inactivates
the CXCR4 ligand, CXCL12. Given the
abundant CXCR4 expression that has
recently been reported on malignant
T cells in MF patches (Kallinich et al.,
2003), the loss of CD26 expression
strongly suggests a potential role for
CXCR4 in the skin-homing of Se´zary
cells (Sokolowska-Wojdylo et al.,
2005; Narducci et al., 2006) (Table 1).
The inactivation of CD26 has been
shown to enhance the migratory po-
tential of cell lines derived from pa-
tients with SS in response to CXCL12,
whereas the presence of soluble CD26
is inhibitory (Narducci et al., 2006).
CXCR4 engagement has previously
been reported to result in the upregula-
tion of the key prosurvival kinases,
PI3K and Akt, with relevance in the
progression of solid malignancies such
as melanoma (Lee et al., 2006). Given
the constitutive expression of CXCL12
in the skin, the loss of CD26 on Se´zary
cells might sustain their chemokine-
driven, cutaneous migration, and acti-
vation of downstream effectors of this
antiapoptotic pathway contributes to
their survival in the skin compartment
(Hwang et al., 2008).
In line with characteristic epidermo-
tropism, the malignant T cells typically
display a CLAþ skin-homing pheno-
type. In addition to CLA interactions,
the unique expression pattern of che-
mokine receptors can in part explain
the cutaneous tropism of the malignant
T cells (Figure 3). Supporting the notion
of a Th2 origin of malignant cells, high
levels of CCR4, but not of CCR5 and
CXCR3 expressions, have recently been
demonstrated on skin-infiltrating T cells
in SS (Fierro et al., 2006). Serum levels
of the related chemokines, CCL17,
CCL22, and CXCL10, are significantly
increased in both SS patients and
patients suffering from erythroderma
due to inflammatory dermatoses. How-
ever, the results from these studies
support the perception of SS being a
Th2 disorder with a selective expres-
sion of CCR4, whereas inflammatory
erythroderma shares overexpression of
both Th1-and Th2-related chemokine
receptors (Fierro et al., 2006).
In addition to the predominant Th2
profile of malignant cells in MF and SS,
Berger et al. (2005), recently reported
the in vitro conversion of malignant
T cells to cells with a Treg pheno-
type after stimulation with cryptic
self-antigens that might be uncovered
during apoptosis. The adoption of Treg-
suppressor functions by CTCL may offer
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Figure 3. Roles for chemokines and their receptors in mycosis fungoides and Se´zary syndrome. Chemokine receptors such as CCR10 and CCR4 permit
skin-specific homing of malignant T cells and support the efficient engagement of DC and the subsequent release of pro-inflammatory cytokines. Apart
from a role in cutaneous homing of Se´zary cells, CXCR4 might sustain their chemokine-driven survival in the skin compartment by activating intracellular
key pro-survival signals. During disease progression, changes in the expression pattern of selected chemokine receptors such as CCR4 and CXCR3 seem to
correlate with reduced epidermotropism of the malignant T cells. The directional migration of CCR7-expressing malignant T cells from the skin to the draining
lymph nodes is effectively supported by the release of CCL19 and CCL21 by stromal cells of the lymphatic vessels and the lymph node.
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a possible explanation for the immuno-
suppressive nature of the disease and
increased susceptibility of MF and SS
patients to opportunistic infections
(Axelrod et al., 1992).
CCR4 and CCR10 in particular
are frequently present on malignant
T cells in MF and SS and play a
potential role in their homing to the
skin (Notohamiprodjo et al., 2005;
Sokolowska-Wojdylo et al., 2005)
(Figure 3). CCL17—a major CCR4
ligand expressed by activated keratino-
cytes, DC, and endothelial cells—is
increased in the serum of MF patients,
with levels correlating with disease
activity (Kakinuma et al., 2003b). Simi-
larly, the CCR10 ligand, CCL27, is
found at elevated levels in patients
with MF and SS and might serve as an
indicator for disease activity (Fujita
et al., 2006; Kagami et al., 2006).
CCR10–CCL27 interactions are pro-
posed to play an early role in the
pathophysiology of MF from the patch
stage. Fujita et al., (2006) reported
significantly higher numbers of circu-
lating CCR10þ CD4þ cells in the
peripheral blood of MF patients com-
pared with those in healthy controls or
patients with AD and an accumulation
of CCR10þ skin-infiltrating tumor
cells in MF lesions. By contrast, serum
levels of CCL27, although considerably
elevated compared with those in
healthy controls, showed no significant
differences in comparison with patients
with AD. In patients with MF and SS,
an unfavorable outcome of the disease
was associated with an overexpression
of CCR4 by malignant CD4þ T cells
(Ishida et al., 2003, 2004b).
Chemokines may not only facili-
tate the recruitment of tumor cells
to certain tissues like the skin but
may also induce tissue infiltration
by various immunosuppressive cells,
such as Tregs, leading to an escape
from immunosurveillance and an
unfavorable outcome in malignant
diseases. Suppressive CCR4-expressing
CD4þCD25 high Tregs are being
recruited to sites of cutaneous lym-
phoma that express high levels of
CCL17 or CCL22 (Ishida et al., 2003).
A change in the expression patterns
of selected chemokine receptors during
disease progression seems to correlate
to the reduced epidermotropism of
malignant T cells generally observed
in skin biopsies from advanced stage
MF and SS. Kallinich et al., (2003)
compared the chemokine receptor
expression in different stages of MF
and reported decreased expression
levels of CCR4 and CXCR3 lesional
skin of tumor-stage patients with MF,
whereas levels of the lymph-node-
homing receptor, CCR7, were remark-
ably increased. Moreover, a recent
report revealed that the addition of
CXCL13 to CCL19 or to CCL21, the
selective CCR7 agonists responsible for
lymph node homing, strongly enhances
the migration of CCR7þ Se´zary cells
(Picchio et al., 2008). Although a
prognostic implication has not yet
been validated, these findings corre-
late with the clinical enlargement of
peripheral lymphnodes and greater
leukemic burden seen in patients with
advanced stage MF.
NEW TOOLS—NEW QUESTIONS
During the past decade, we have
observed the development of potent
immunotherapeutics directed against
surface molecules that are involved
in the migration and/or function of
immune cells. The diversity of chemo-
kine receptors and their preferred
expression on distinct leukocyte sub-
sets that have been implicated in the
pathogenesis of different inflammatory
or neoplastic diseases offer the oppor-
tunity for their selective targeting.
Monoclonal antibodies that target
inflammatory cytokines or adhesion
molecules, such as the anti-a4-integrin
mAb, Natalizumab, have been suc-
cessfully used for the treatment of
inflammatory and autoimmune dis-
eases (von Andrian and Mackay,
2000). However, given the consider-
able promiscuity in the chemokine
network, with multiple chemokines
often sharing the same receptor, strate-
gies favoring the selective targeting
and inactivation of chemokines by
blocking antibodies seem to be less
promising.
Conversely, agents that block che-
mokine receptors expressed on distinct
leucocyte subsets are expected to be
more specific. In preclinical studies,
mAbs directed against CCR4 success-
fully controlled CCR4-expressing
malignant T-cell clones by eliciting
antibody-dependent natural killer-
mediated cytotoxicity (Niwa et al.,
2004; Ishida et al., 2004b).
However, a distinct chemokine
receptor expression has not only been
documented on subsets of pathogenic
T cells in various disease but also on
immune cells exerting regulatory func-
tion, such as Treg cells (Kleinewietfeld
et al., 2005). Notably, the antibody
used in the described study did not
only lyse malignant CCR4þ T-cells
in vitro but also reduced the expression
of Foxp3 mRNA, suggesting a possible
effect in depleting regulatory T cells
(Ishida et al., 2004a, b). Although the
inhibition of Treg functions by means
of chemokine receptor antagonism has
been demonstrated to be favorable
for tumor control, the disruption of
normal endogenous immune regulatory
mechanisms may result in broader,
unfavorable effects, such as increased
inflammatory responses and risk for
infection (Unsoeld et al., 2007).
A new approach takes advantage
of the physiological endocytosis of
chemokine receptors after ligation,
eventually enhancing the presentation
of tumor-derived peptides on the cell
surface (Biragyn et al., 2004). Data
from a recently published animal
study provided proof-of-principle that
chemokine receptor-expressing tumors
can be successfully controlled by the
delivery of toxins through their chemo-
kine receptors (Baatar et al., 2007).
Biragyn and colleagues have gener-
ated chemokine-toxin fusion proteins,
chemokines fused with toxic moieties
that are nontoxic unless delivered
into the cell cytosol. Treatment
with CCL17-expressing chemotoxin
efficiently eradicated CCR4-expressing
CTCL established in NOD-SCID mice
(Baatar et al., 2007). While strengthen-
ing the concept that the targeting of
chemokine receptors such as CCR4 or
CCR10 permits the control of growth
and dissemination of certain tumors,
this study on the whole showcases
the complexity and challenges in
the field. Despite the initial tumor
control by CCL17-chemotoxin treat-
ment, the malignancy eventually
relapsed. Importantly, after tumor
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relapse, the malignant cells seemed
resistant to additional and repeated
treatment with the chemokine toxin. It
remains to be seen whether such a
highly specific treatment in hetero-
genous malignancies selects for tumor
variants and thus supports the out-
growth of tumors with an aberrant
receptor expression.
During the last decade, particular
attention has been paid to the devel-
opment of small molecule antagonists
directed against chemokine receptors.
As synthetic small-molecule anta-
gonists directed against G-protein-
coupled receptors have been used
effectively in the treatment of various
diseases, the finding that chemokines
signal through this large class of recep-
tors has raised hope for their thera-
peutic application in targeting specific
chemokine receptors.
Nevertheless, despite intense
research efforts and promising results
from animal studies more than
two decades after the discovery of
chemokines and their receptors, only
few synthetic receptor antagonists
have found their way into a clinical
application.
Recently, the small-molecule anta-
gonist, Mavaviroc, directed against the
HIV co-receptor, CCR5, became the
first Food and Drug Administration-
approved antiretroviral agent that
targets a human host protein rather
than a viral component (MacArthur
and Novak, 2008). AMG487, a small-
molecule antagonist directed against
CXCR3 from Tularik-Amgen, pro-
gressed to Phase II clinical trials for
the treatment of psoriasis in 2003,
but has been withdrawn because of
lack of efficacy. Although the signifi-
cance of the relative contribution of
Th1 cells opposed to that of Th17 cells
in autoimmune inflammatory diseases
such as psoriasis is not yet fully under-
stood, data from preclinical studies in
rheumatoid arthritis models suggest
that CCR6 inhibition holds promise
for the treatment of Th17-related dis-
eases (Hirota et al., 2007). Although
a small-molecule antagonist directed
against CCR6 has yet to be developed,
the targeting of a different subset of
pathogenic effector T cells in psoriasis
by means of CCR6 inhibition may be
particularly effective and reasonable in
combination with established systemic
therapies targeting Th1-related cyto-
kines, such as the anti-TNF-a mAbs
(Eternacept, Infliximab).
Another noteworthy level of com-
plexity is added by the finding that
some chemokines may naturally exert
either agonistic or antagonistic effects.
An emerging concept in the field
is the regulation of Th1 and Th2
responses by natural chemokine anta-
gonism. The Th2-type associated
chemokine, CCL26, an agonist for
CCR3, has been found to be an
antagonist for CCR2, thus, negatively
regulating the migration of human
monocytes (Ogilvie et al., 2003), and
in a model of allergen-induced airway
inflammation, the CXCR3 ligand,
CXCL9, which is generally asso-
ciated with Th1-responses, evolved
as a negative regulator of eosinophil
recruitment by the antagonism of CCR3
(Fulkerson et al., 2004). The demon-
stration that a chemokine can function
both as an agonist for one and as an
antagonist for a different chemokine
receptor has added another level to
the regulation of Th1/Th2-mediated
responses, with possible implications for
the development of anti-inflammatory
therapies.
Truncated or otherwise modified
chemokines have demonstrated pro-
found inhibitory effects on inflam-
matory responses in several animal
models, providing ground for optimism
for the many ongoing human trials
(reviewed by Mackay, 2008).
An additional, yet widely ignored
strategy is the exploitation of chemo-
kine decoy receptors to fine-tune the
distribution and bioavailability of
chemokines. The broad specificity of
decoy receptors with a distinct set
of ligands may identify them as
valuable tools of efficient chemokine-
targeting strategies in the therapy and
prophylaxis of various diseases.
The appreciation of the role of
chemokines and their receptors in
leukocyte trafficking and other key
biological functions suggests a pro-
mising potential for their therapeutic
targeting in a wide range of diseases.
In practice, however, the strategy to
antagonize chemokine receptors in
order to therapeutically control the
homing of pathogenic T cells to the
cutaneous compartment has proven
to be challenging. Over the years,
the close association of chemokine
receptor expression with the func-
tional properties of T-cell subsets has
been convincingly documented and
the key molecules have been well
defined. However, several key concep-
tual issues based on the experimental
evidence outlined above have risen
in recent years and future studies will
need to address these key challenges.
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